JP7591406B2 - トランスフォーミング増殖因子ベータ抵抗性ナチュラルキラー細胞 - Google Patents

トランスフォーミング増殖因子ベータ抵抗性ナチュラルキラー細胞 Download PDF

Info

Publication number
JP7591406B2
JP7591406B2 JP2020562093A JP2020562093A JP7591406B2 JP 7591406 B2 JP7591406 B2 JP 7591406B2 JP 2020562093 A JP2020562093 A JP 2020562093A JP 2020562093 A JP2020562093 A JP 2020562093A JP 7591406 B2 JP7591406 B2 JP 7591406B2
Authority
JP
Japan
Prior art keywords
cells
cell
tgf
tgfβi
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020562093A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512164A5 (https=
JPWO2019152387A5 (https=
JP2021512164A (ja
Inventor
アンソニー リー，ディーン
アン フォルツ－ストリングフェロー，ジェニファー
エドワーズ－モーズマン，ジェナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nationwide Childrens Hospital Inc
Original Assignee
Nationwide Childrens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nationwide Childrens Hospital Inc filed Critical Nationwide Childrens Hospital Inc
Publication of JP2021512164A publication Critical patent/JP2021512164A/ja
Publication of JP2021512164A5 publication Critical patent/JP2021512164A5/ja
Publication of JPWO2019152387A5 publication Critical patent/JPWO2019152387A5/ja
Priority to JP2024200825A priority Critical patent/JP2025026937A/ja
Application granted granted Critical
Publication of JP7591406B2 publication Critical patent/JP7591406B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4225—Growth factors
    • A61K40/4229—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020562093A 2018-01-30 2019-01-29 トランスフォーミング増殖因子ベータ抵抗性ナチュラルキラー細胞 Active JP7591406B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024200825A JP2025026937A (ja) 2018-01-30 2024-11-18 トランスフォーミング増殖因子ベータ抵抗性ナチュラルキラー細胞

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862623682P 2018-01-30 2018-01-30
US62/623,682 2018-01-30
PCT/US2019/015617 WO2019152387A1 (en) 2018-01-30 2019-01-29 Transforming growth factor beta-resistant natural killer cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024200825A Division JP2025026937A (ja) 2018-01-30 2024-11-18 トランスフォーミング増殖因子ベータ抵抗性ナチュラルキラー細胞

Publications (4)

Publication Number Publication Date
JP2021512164A JP2021512164A (ja) 2021-05-13
JP2021512164A5 JP2021512164A5 (https=) 2022-01-27
JPWO2019152387A5 JPWO2019152387A5 (https=) 2022-01-27
JP7591406B2 true JP7591406B2 (ja) 2024-11-28

Family

ID=67478491

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020562093A Active JP7591406B2 (ja) 2018-01-30 2019-01-29 トランスフォーミング増殖因子ベータ抵抗性ナチュラルキラー細胞
JP2024200825A Pending JP2025026937A (ja) 2018-01-30 2024-11-18 トランスフォーミング増殖因子ベータ抵抗性ナチュラルキラー細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024200825A Pending JP2025026937A (ja) 2018-01-30 2024-11-18 トランスフォーミング増殖因子ベータ抵抗性ナチュラルキラー細胞

Country Status (12)

Country Link
US (1) US20200368281A1 (https=)
EP (1) EP3746118A4 (https=)
JP (2) JP7591406B2 (https=)
KR (2) KR20250093419A (https=)
CN (1) CN111818941A (https=)
AU (1) AU2019213678B2 (https=)
BR (1) BR112020015490A2 (https=)
CA (1) CA3090096A1 (https=)
IL (2) IL276374B2 (https=)
MX (1) MX2020008044A (https=)
SG (1) SG11202007288VA (https=)
WO (1) WO2019152387A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023517220A (ja) * 2020-03-11 2023-04-24 リサーチ インスティテュート アット ネイションワイド チルドレンズ ホスピタル 微生物感染症の治療のためのｎｋ細胞およびそれらの使用
AU2021263579A1 (en) * 2020-04-30 2022-12-01 Research Institute At Nationwide Children's Hospital Overcoming immune suppression with TGF-β resistant NK cells
KR20250154429A (ko) * 2023-03-02 2025-10-28 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 암 면역요법을 위한 형질전환 성장인자-베타 슈퍼패밀리가 각인된 자연살해세포

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170056448A1 (en) 2015-09-01 2017-03-02 Ifm Therapeutics, Inc Immune cells having increased immunity or resistance to an immunosuppressive cytokine and use of the same
JP2017532353A (ja) 2014-10-27 2017-11-02 ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド ナチュラルキラー細胞のための方法及び組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2058388A1 (en) * 2007-10-05 2009-05-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Non-conventional NKT cells for use in cancer therapy
WO2015103793A1 (zh) * 2014-01-13 2015-07-16 深圳市汉科生物工程有限公司 用带有活性因子的细胞空壳作为淋巴细胞体外培养增效剂的制备及其应用方法
WO2017048809A1 (en) * 2015-09-14 2017-03-23 Regents Of The University Of Minnesota Nk cells exhibiting an adaptive phenotype and methods for preparing and for using

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017532353A (ja) 2014-10-27 2017-11-02 ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド ナチュラルキラー細胞のための方法及び組成物
US20170056448A1 (en) 2015-09-01 2017-03-02 Ifm Therapeutics, Inc Immune cells having increased immunity or resistance to an immunosuppressive cytokine and use of the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Annu.Rev.Immunol.，2005年，24 ，pp.99-146
Cancer Res.，2009年，69(9) ，pp.4010-4017, page 1-16
Immunity，2006年，24，pp.575-590

Also Published As

Publication number Publication date
AU2019213678A1 (en) 2020-09-03
AU2019213678B2 (en) 2025-06-26
EP3746118A4 (en) 2021-11-24
US20200368281A1 (en) 2020-11-26
KR20250093419A (ko) 2025-06-24
IL309656A (en) 2024-02-01
EP3746118A1 (en) 2020-12-09
IL276374B1 (en) 2024-01-01
IL276374A (en) 2020-09-30
RU2020127722A (ru) 2022-02-28
MX2020008044A (es) 2020-12-10
KR20200118449A (ko) 2020-10-15
IL276374B2 (en) 2024-05-01
JP2025026937A (ja) 2025-02-26
CA3090096A1 (en) 2019-08-08
CN111818941A (zh) 2020-10-23
SG11202007288VA (en) 2020-08-28
KR102822300B1 (ko) 2025-06-17
WO2019152387A1 (en) 2019-08-08
BR112020015490A2 (pt) 2021-03-23
JP2021512164A (ja) 2021-05-13

Similar Documents

Publication Publication Date Title
JP7604000B2 (ja) 改変ヒト初代血液樹状細胞株を生成するための方法
Morris et al. Advances in the understanding of acute graft‐versus‐host disease
JP2025026937A (ja) トランスフォーミング増殖因子ベータ抵抗性ナチュラルキラー細胞
JP2017525364A (ja) 免疫細胞を惹起及び／又は活性化するための免疫応答刺激性サイトカインを発現する遺伝子改変型間葉系幹細胞
WO2009097140A1 (en) Methods for off -the -shelf tumor immunotherapy using allogeneic t-cell precursors
CN108697737A (zh) 在免疫疗法中使用的组合物
Torelli et al. Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission
KR101867942B1 (ko) 바이러스 항원 특이적인 t 세포의 유도 및 증식 방법
US11981924B2 (en) Composition for culturing NK cells and method for culturing NK cells using same
JP7681908B2 (ja) Ｃｃｒ２＋造血幹細胞は養子細胞療法におけるｔ細胞活性化を媒介する
US20210292427A1 (en) Method for treating tumor using immune effector cell
Valencic et al. Inhibition of mesenchymal stromal cells by pre-activated lymphocytes and their culture media
JP6334810B2 (ja) Ｉｆｎを用いた非接着培養による樹状細胞の調製方法
RU2830178C2 (ru) Естественные клетки-киллеры, резистентные к трансформирующему ростовому фактору бета
KR102032384B1 (ko) 제대혈 단핵세포에서의 자연살해세포의 제조 방법
Xiao et al. EBV-induced human CD8+ NKT cells synergise CD4+ NKT cells suppressing EBV-associated tumours upon induction of Th1-bias
CN112399858A (zh) 医学用途
Galaverna Outcome and immune reconstitution of children and young adults with acute leukemia after alfa/beta T-cell and B-cell depleted HLA-Haploidentical transplantation
HK40047175A (en) Medical uses
HK40016402A (en) Ccr2+hematopoietic stem cells mediate t cell activation in adoptive cell therapy
MUTIS et al. Main Session III
HK40016402B (zh) 过继细胞疗法中ccr2+造血干细胞介导的t细胞激活
JPWO2004016774A1 (ja) 抑制性ｎｋ細胞受容体陽性細胞の増幅方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220119

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230508

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230725

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240326

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240813

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241022

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241118

R150 Certificate of patent or registration of utility model

Ref document number: 7591406

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150